van den Bent MJ, Tesileanu CMS, Wick W, et al. - Addition of concurrent, adjuvant, and both current and adjuvant temozolomide to radiotherapy among adults with newly diagnosed 1p/19q non-co-deleted anaplastic gliomas was inquired in the CATNON trial, there is lack of clarity about the advantage of concurrent temozolomide chemotherapy as well as the relevance of mutations in the IDH1 and IDH2 genes, researchers undertook this randomised, open-label, phase 3 study wherein they randomized (1:1:1:1) patients (aged 18 years or older with newly diagnosed 1p/19q non-co-deleted anaplastic gliomas and a WHO performance status of 0–2) to radiotherapy alone, radiotherapy with concurrent oral temozolomide, radiotherapy with adjuvant oral temozolomide, or radiotherapy with both concurrent and adjuvant temozolomide. Findings demonstrated a survival benefit in relation to adjuvant temozolomide chemotherapy, but not concurrent temozolomide chemotherapy, in patients with 1p/19q non-co-deleted anaplastic glioma. Clinical advantage depended on IDH1 and IDH2 mutational status.